Real-World Studies
Adjuvant ICI and Chemotherapy Linked to Longer DFS in High-Risk UTUC
Washino et alInternational journal of urology : official journal of the Japanese Urological Association

In this multicenter retrospective study, researchers evaluated the impact of adjuvant immune checkpoint inhibitors (ICIs) and adjuvant chemotherapy on survival outcomes following radical nephroureterectomy in patients with upper tract urothelial carcinoma (UTUC) at high risk of recurrence. The cohort included 243 patients divided into three cohorts: observation/no adjuvant therapy (n = 151), adjuvant chemotherapy (n = 59), and adjuvant ICI therapy (n = 33). Baseline clinicopathological characteristics were largely comparable across cohorts. The primary endpoint was disease-free survival (DFS), with additional evaluations of non-urothelial tract and urothelial tract recurrence-free survival.
In multivariable Cox proportional hazards analyses of the 2-month landmark cohort, both adjuvant treatment strategies were associated with reduced risk of recurrence compared with no adjuvant therapy. Adjuvant ICI was associated with a lower hazard of DFS events (HR, 0.374; 95% CI, 0.175–0.721; p = 0.003), as was adjuvant chemotherapy (HR, 0.540; 95% CI, 0.338–0.846; p = 0.007). In secondary survival analyses, adjuvant ICI was associated with longer non-urothelial tract recurrence-free survival versus observation, while urothelial tract recurrence-free survival did not differ significantly among the groups. The study authors concluded that both adjuvant ICI and adjuvant chemotherapy were associated with longer DFS after radical nephroureterectomy in high-risk UTUC, noting that longer follow-up and prospective trials are needed to assess the durability of these outcomes and the comparative effectiveness between ICI and chemotherapy.
Key Takeaways
- In a multivariable 2-month landmark analysis, adjuvant immune checkpoint inhibitor therapy was associated with a reduced hazard of disease-free survival events (HR, 0.374; 95% CI, 0.175–0.721; p = 0.003) compared with no adjuvant therapy.
- Adjuvant chemotherapy was also associated with a reduced hazard of disease-free survival events (HR, 0.540; 95% CI, 0.338–0.846; p = 0.007) compared with no adjuvant therapy.
- Adjuvant immune checkpoint inhibitor therapy was associated with longer non-urothelial tract recurrence-free survival compared with no adjuvant therapy, whereas urothelial tract recurrence-free survival did not differ significantly among the treatment groups.
Read the original sourceInternational journal of urology : official journal of the Japanese Urological Association
